Pursuing breakthrough solutions to CNS disorders through the development of next-gen pre-emptive & disease-modifying interventions
Focused on novel, neuroprotective compounds that restore neuronal function, we develope innovative disease-modifying therapeutics for patients with neurological disorders by leveraging proven mechanisms of action and next generation of neuroplastogens for their ability to stimulate neuroplasticity, reduce neuro-inflammation and promote neuro-rejuvenation.
Our lead program (PUR501) is a third generation 5-HT2A partial agonist, non-hallucinogenic neuroplastogen Novel Chemical Entity (NCE) with safe cardiovascular profile, followed by a second generation HDAC6 inhibitor NCE (PUR400 series) that enhances the clearance of protein aggregates and improve axonal transport, thereby protecting neurons from damages.
Complementing our drug development efforts, PurMinds’ NeuroLab holds a Health Canada issued license for controlled substances that allows us to produce, process, sell and export a variety of psychoactive compounds, including a proprietary botanical Psilocybin program.
OUR MISSION is to develop best-in-class disease-modifying therapeutics for neurological and psychiatric conditions. We recognize that there is an urgent unmet need for innovative medicines for CNS disorders, as current treatments primarily focus on managing symptomology rather than addressing underlying issues. At PurMinds, our goal is to innovate next generation therapeutic and pre-emptive interventions that target the root cause to prevent disease progression, improve long-term outcomes and, most importantly, enhance patients’ quality of life.
Tackling the Vast Unmet
Medical Needs
​
Global API Supply &
Formulation